Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + PD-1 monoclonal antibody
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination involves **lenvatinib**, a multiple receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) receptors, and a **PD-1 monoclonal antibody**, which enhances the immune system's ability to detect and fight tumor cells by blocking the PD-1/PD-L1 interaction. The combination has shown promise in treating various cancers, including advanced endometrial carcinoma and hepatocellular carcinoma (HCC), by modulating the tumor microenvironment and enhancing antitumor immune responses.
- Brand names
- LENVIMA + KEYTRUDA
- Other names
- Combination of lenvatinib and PD-1 monoclonal antibody
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on lenvatinib + PD-1 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + PD-1 monoclonal antibody.